Medicine and Dentistry
Neoplasm
100%
Immunotherapy
47%
Malignant Neoplasm
44%
Mesothelioma
43%
Cisplatin
37%
Immune Checkpoint Blockade
34%
Tumor Microenvironment
27%
Lymphocyte
26%
Tumor Immunity
20%
Tumor Cell
20%
Pleura Mesothelioma
18%
Dendritic Cell
16%
Melanoma
16%
Antineoplastic Activity
15%
Cancer Chemotherapy
15%
Durvalumab
15%
Pleura Effusion
15%
Polyinosinic Polycytidylic Acid
15%
Pemetrexed
15%
Immune Response
14%
Cancer Immunotherapy
13%
Biological Marker
13%
Cytotoxic T-Cell
12%
CTLA-4
12%
Arm
12%
Cancer
12%
Cancer Recurrence
11%
Clinical Study
11%
T Cell
11%
Overall Survival
10%
Cancer Cell
10%
Cytoreductive Surgery
10%
Debulking Surgery
10%
Diseases
10%
Treatment Response
10%
Clinical Trial
9%
Local Therapy
9%
Tumor Infiltrating Lymphocyte
8%
First-Line Chemotherapy
8%
Receptor
8%
Carboplatin
7%
Cancer Immunization
7%
STAT1 Protein
7%
Tretinoin
7%
Neoadjuvant Therapy
7%
Cyclophosphamide
7%
Soft Tissue Sarcoma
7%
Dexamethasone
7%
Combination Drug
7%
Protein Tyrosine Kinase
7%
Immunology and Microbiology
Immune Checkpoint Blockade
47%
Immunotherapy
45%
Cytotoxic T-Cell
35%
Murine
22%
Cancer Immunotherapy
22%
Interferon Type I
20%
Tumor Antigen
20%
Tumor Cell
19%
Dendritic Cell
19%
T Cell Receptor
19%
T Cell
18%
Cross-Presentation
15%
Cyclophosphamide
15%
Tumor Immunity
15%
Antigen Specificity
14%
T-Helper Cell
14%
Lymphocyte
13%
Immunocompetent Cell
13%
RNA Sequence
12%
Immune Response
12%
Tumor-Associated Macrophage
11%
CTLA-4
10%
Programmed Death-Ligand 1
10%
Peripheral Blood Lymphocyte
10%
Dexamethasone
9%
Gene Expression
9%
Tumor-Infiltrating Lymphocytes
8%
Regulatory T Cell
8%
Lymph Node
8%
Maximum Tolerated Dose
8%
Mediator
8%
Dynamics
7%
Neoantigen
7%
Sensitization
7%
Tumor Necrosis Factor Alpha
7%
Cell Population
7%
Trastuzumab
7%
Transforming Growth Factor Beta
7%
STAT1
7%
Epithelial Mesenchymal Transition
7%
Xenograft
7%
Metabolite
7%
Tyrosine
7%
Immune System
7%
Cytotoxic T Cell
6%
CD8
6%
Peptides
5%
RNA Sequencing
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
71%
Malignant Neoplasm
56%
Chemotherapy
39%
Mesothelioma
36%
Cisplatin
27%
Pleura Mesothelioma
26%
Immunotherapy
22%
Tumor Microenvironment
20%
Cytotoxic T Lymphocyte Antigen 4
17%
Durvalumab
15%
Retinoic Acid
15%
Polyinosinic Polycytidylic Acid
13%
Cytotoxic Chemotherapy
10%
Dexamethasone
9%
Receptor
9%
CD8 Antigen
9%
First-Line Chemotherapy
8%
Melanoma
8%
Cancer Chemotherapy
7%
Drug Discovery
7%
Cancer Recurrence
7%
Cyclophosphamide
7%
STAT1 Protein
7%
Peroxisome Proliferator Activated Receptor
7%
Pleura Effusion
7%
Geldanamycin
7%
Protein Tyrosine Kinase
7%
Trastuzumab
7%
Combination Drug
7%
Maximum Tolerated Dose
7%
STAT Protein
7%
Transforming Growth Factor Beta
7%
Esophageal Adenocarcinoma
7%
Toll Like Receptor Agonist
7%
Biological Marker
7%
Pemetrexed
7%
Combination Therapy
7%
Diseases
6%
Adverse Event
6%
Effusion
6%
Carboplatin
5%
Interferon
5%
Monotherapy
5%
Murine
5%
Cancer Model
5%
Chemoradiation Therapy
5%
Head and Neck Squamous Cell Carcinoma
5%